We are live on
!
Find out more
GCP
GSA Capital Partners Portfolio holdings
AUM
$1.59B
1-Year Est. Return
39.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.65%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$1.01B
AUM Growth
+$205M
(+25%)
Cap. Flow
+$234M
Cap. Flow
% of AUM
23.15%
Top 10 Holdings %
Top 10 Hldgs %
4.25%
Holding
2,085
New
689
Increased
399
Reduced
339
Closed
654
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
National Vision
EYE
|
+$5.45M |
| 2 |
Altimmune
ALT
|
+$4.45M |
| 3 |
FRC
First Republic Bank
FRC
|
+$4.06M |
| 4 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$3.99M |
| 5 |
Hilton Worldwide
HLT
|
+$3.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PG&E
PCG
|
+$7.74M |
| 2 |
Dropbox
DBX
|
+$3.02M |
| 3 |
Progressive
PGR
|
+$2.77M |
| 4 |
Southwest Airlines
LUV
|
+$2.69M |
| 5 |
Transocean
RIG
|
+$2.59M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.8% |
| 2 | Consumer Discretionary | 14.87% |
| 3 | Healthcare | 14.13% |
| 4 | Financials | 11.49% |
| 5 | Industrials | 11.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1326
Bridgewater Bancshares
BWB
$603M
| $129K | 0.01% |
+11,941
| New | +$175K |
|
|
VWE
1327
DELISTED
Vintage Wine Estates, Inc. Common Stock
VWE
| $129K | 0.01% |
+120,692
| New | +$250K |
|
1328
Nektar Therapeutics
NKTR
$2.58B
| $127K | 0.01% |
12,024
-30,978
| -72% | -$937K |
|
1329
Vera Therapeutics
VERA
$2.36B
| $126K | 0.01% |
+16,272
| New | +$126K |
|
1330
Passage Bio
PASG
$14.1M
| $125K | 0.01% |
6,509
+1,167
| +22% | +$31.6K |
|
1331
Acacia Research
ACTG
$470M
| $120K | 0.01% |
31,131
-85,333
| -73% | -$361K |
|
1332
ARKO Corp
ARKO
$635M
| $120K | 0.01% |
+14,151
| New | +$118K |
|
1333
Expensify
EXFY
$245M
| $119K | 0.01% |
+14,618
| New | +$130K |
|
|
NESR
1334
National Energy Services Reunited Corp
NESR
$2.93B
| $118K | 0.01% |
+22,513
| New | +$149K |
|
1335
Harvard Bioscience
HBIO
$29.2M
| $117K | 0.01% |
2,785
-8,748
| -76% | -$259K |
|
1336
Heritage Insurance Holdings
HRTG
$991M
| $117K | 0.01% |
37,875
-177,496
| -82% | -$462K |
|
1337
Arbutus Biopharma
ABUS
$915M
| $116K | 0.01% |
38,160
-79,031
| -67% | -$223K |
|
|
HDSN
1338
Hudson Technologies
HDSN
$235M
| $116K | 0.01% |
13,250
-33,407
| -72% | -$323K |
|
1339
Janus International
JBI
$757M
| $116K | 0.01% |
11,799
-23,255
| -66% | -$242K |
|
1340
Full Truck Alliance
YMM
$9.99B
| $116K | 0.01% |
15,214
-49,749
| -77% | -$394K |
|
|
GOEV
1341
DELISTED
Canoo Inc. Class A Common Stock
GOEV
| $116K | 0.01% |
386
+315
| +444% | +$133K |
|
|
CCC
1342
CCC Intelligent Solutions
CCC
$4.08B
| $114K | 0.01% |
+12,764
| New | +$114K |
|
|
IMGN
1343
DELISTED
Immunogen Inc
IMGN
| $114K | 0.01% |
+29,800
| New | +$127K |
|
1344
Amneal Pharmaceuticals
AMRX
$5.79B
| $112K | 0.01% |
80,519
-94,530
| -54% | -$188K |
|
1345
Vera Bradley
VRA
$98.7M
| $112K | 0.01% |
+18,697
| New | +$105K |
|
|
VNET
1346
VNET Group
VNET
$2.09B
| $111K | 0.01% |
+34,300
| New | +$168K |
|
|
TVRD
1347
Tvardi Therapeutics
TVRD
$23.4M
| $111K | 0.01% |
+626
| New | +$210K |
|
1348
Grove Collaborative
GROV
$46.1M
| $109K | 0.01% |
+49,824
| New | +$115K |
|
1349
Outlook Therapeutics
OTLK
$191M
| $107K | 0.01% |
4,892
-8,997
| -65% | -$201K |
|
1350
FerroAtlántica
GSM
$839M
| $104K | 0.01% |
21,100
-11,257
| -35% | -$52K |
|
Similar funds
NCL
DG
VNT
SS
GWANC
LCM
LCM
FDCP
GSA Capital Partners's Q1 2023 Portfolio in Review
As of Q1 2023, GSA Capital Partners held 2,085 positions worth $1.01B, up 25% from $806M the previous quarter. Its ten largest holdings account for 4.2% of the portfolio.
GSA Capital Partners deployed $234M of net new capital in Q1 2023, opening 689 new positions and adding to 399 existing holdings. Its largest new stake was National Vision: 167,499 shares worth $3.16M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Transocean, an estimated $2.59M trimmed.
- GSA Capital Partners's largest Q1 2023 buy was National Vision: 167,499 shares worth $3.16M.
- GSA Capital Partners added most to Altimmune in Q1 2023, an estimated $4.45M increase.
- GSA Capital Partners's biggest Q1 2023 reduction was Transocean, cutting an estimated $2.59M.
- GSA Capital Partners fully exited PG&E in Q1 2023, selling an estimated $7.74M.
- GSA Capital Partners's ten largest holdings make up 4.2% of its $1.01B portfolio in Q1 2023.
- GSA Capital Partners opened 689 new positions and closed 654 in Q1 2023.
- GSA Capital Partners's portfolio value rose 25% quarter-over-quarter to $1.01B.
Based on GSA Capital Partners's 13F filing for Q1 2023, filed 12 May 2023.